Swiss National Bank purchased a new position in shares of Axonics Modulation Technologies Inc (NASDAQ:AXNX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 18,100 shares of the company’s stock, valued at approximately $742,000. Swiss National Bank owned approximately 0.06% of Axonics Modulation Technologies as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also modified their holdings of the company. EAM Global Investors LLC acquired a new stake in shares of Axonics Modulation Technologies during the first quarter worth about $1,483,000. Granite Investment Partners LLC acquired a new stake in shares of Axonics Modulation Technologies during the first quarter worth about $848,000. Westfield Capital Management Co. LP acquired a new stake in shares of Axonics Modulation Technologies during the first quarter worth about $261,000. Deutsche Bank AG acquired a new stake in shares of Axonics Modulation Technologies during the fourth quarter worth about $137,000. Finally, Ibex Investors LLC acquired a new stake in shares of Axonics Modulation Technologies during the second quarter worth about $245,000. 33.75% of the stock is currently owned by institutional investors and hedge funds.
AXNX has been the topic of several research reports. Zacks Investment Research raised shares of Axonics Modulation Technologies from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 14th. Wells Fargo & Co upped their target price on shares of Axonics Modulation Technologies from $35.00 to $47.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 2nd. Bank of America upped their target price on shares of Axonics Modulation Technologies from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Needham & Company LLC assumed coverage on shares of Axonics Modulation Technologies in a research note on Tuesday, September 3rd. They set a “buy” rating and a $43.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $33.65.
In other Axonics Modulation Technologies news, SVP Michael V. Williamson sold 5,000 shares of the stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $36.01, for a total value of $180,050.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Raymond W. Cohen purchased 3,500 shares of the company’s stock in a transaction on Tuesday, August 6th. The stock was bought at an average price of $30.41 per share, for a total transaction of $106,435.00. The disclosure for this purchase can be found here. Insiders have sold 11,695 shares of company stock worth $458,663 over the last 90 days. Insiders own 35.99% of the company’s stock.
Shares of AXNX stock traded up $0.14 during trading hours on Friday, reaching $31.65. 9,593 shares of the stock were exchanged, compared to its average volume of 173,308. The business’s fifty day moving average is $34.59 and its two-hundred day moving average is $30.02. The company has a debt-to-equity ratio of 0.18, a current ratio of 12.21 and a quick ratio of 11.51. Axonics Modulation Technologies Inc has a 12-month low of $11.95 and a 12-month high of $43.37. The firm has a market capitalization of $874.00 million and a P/E ratio of -6.82.
Axonics Modulation Technologies (NASDAQ:AXNX) last released its earnings results on Monday, August 5th. The company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.17). Axonics Modulation Technologies had a negative return on equity of 59.67% and a negative net margin of 1,515.61%. The firm had revenue of $1.49 million for the quarter, compared to analysts’ expectations of $1.04 million. The business’s revenue for the quarter was up 12300.0% compared to the same quarter last year. As a group, equities research analysts predict that Axonics Modulation Technologies Inc will post -2.28 earnings per share for the current fiscal year.
Axonics Modulation Technologies Company Profile
Axonics Modulation Technologies, Inc, a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention.
See Also: What is the NASDAQ Stock Market?
Receive News & Ratings for Axonics Modulation Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics Modulation Technologies and related companies with MarketBeat.com's FREE daily email newsletter.